Guardant Health - GH Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $40.40
Forecasted Upside: 130.33%
Number of Analysts: 12
Breakdown:
0 Sell Ratings
2 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$17.54 As of 04/23/2024 10:46 AM ET

▼ -0.05 (-0.28%)

1 month | 3 months | 12 months

Get New Guardant Health Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for GH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GH

^$40.40

▲ +130.33% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $40.40, with a high forecast of $55.00 and a low forecast of $27.00. The average price target represents a 130.33% upside from the last price of $17.54.

Current Consensus is Moderate Buy

The current consensus among 12 investment analysts is to moderate buy stock in Guardant Health. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/31/2022

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/29/2023

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/29/2023

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

7/28/2023

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

10/26/2023

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

1/24/2024

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/24/2024

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

4/23/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/15/2024	The Goldman Sachs Group	Lower Target	Buy ➝ Buy	$32.00 ➝ $28.00	Low
4/5/2024	Guggenheim	Reiterated Rating	Neutral		Low
2/26/2024	Piper Sandler	Lower Target	Overweight ➝ Overweight	$40.00 ➝ $30.00	Low
2/23/2024	JPMorgan Chase & Co.	Lower Target	Overweight ➝ Overweight	$60.00 ➝ $45.00	Low
2/23/2024	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$50.00 ➝ $45.00	Low
1/29/2024	The Goldman Sachs Group	Lower Target	Buy ➝ Buy	$43.00 ➝ $37.00	Low
12/14/2023	Guggenheim	Initiated Coverage	Neutral		Low
12/13/2023	Wolfe Research	Initiated Coverage	Peer Perform		Low
11/13/2023	Raymond James	Upgrade	Market Perform ➝ Outperform	$27.00	Low
11/8/2023	Morgan Stanley	Lower Target	Overweight ➝ Overweight	$55.00 ➝ $50.00	Low
10/20/2023	The Goldman Sachs Group	Lower Target	Buy ➝ Buy	$52.00 ➝ $45.00	Low
10/2/2023	Citigroup	Reiterated Rating	Buy ➝ Buy	$50.00	Low
9/28/2023	Sanford C. Bernstein	Initiated Coverage	Outperform	$34.00	Low
9/27/2023	Piper Sandler	Upgrade	Neutral ➝ Overweight	$40.00	Low
9/8/2023	William Blair	Reiterated Rating	Outperform		Low
8/8/2023	Piper Sandler	Boost Target	Neutral ➝ Neutral	$30.00 ➝ $40.00	Low
8/7/2023	Morgan Stanley	Lower Target	Overweight ➝ Overweight	$60.00 ➝ $55.00	Low
8/4/2023	Citigroup	Boost Target	Buy ➝ Buy	$40.00 ➝ $50.00	Low
5/26/2023	Citigroup	Upgrade	Neutral ➝ Buy	$28.00 ➝ $40.00	Low
5/15/2023	Piper Sandler	Lower Target		$35.00 ➝ $30.00	Low
5/10/2023	Credit Suisse Group	Lower Target		$60.00 ➝ $55.00	Low
5/5/2023	UBS Group	Initiated Coverage	Buy	$40.00	Low
3/9/2023	Citigroup	Downgrade	Buy ➝ Neutral	$60.00 ➝ $33.00	Low
3/3/2023	Piper Sandler	Lower Target	Neutral	$50.00 ➝ $35.00	Low
2/27/2023	Morgan Stanley	Lower Target	Overweight	$73.00 ➝ $66.00	Low
2/24/2023	BTIG Research	Lower Target	Buy	$60.00 ➝ $50.00	Low
2/24/2023	Credit Suisse Group	Lower Target	Outperform	$70.00 ➝ $60.00	Low
2/24/2023	Canaccord Genuity Group	Lower Target	Buy	$65.00 ➝ $60.00	Low
2/24/2023	Cowen	Lower Target	Outperform	$70.00 ➝ $53.00	Low
2/24/2023	JPMorgan Chase & Co.	Lower Target	Overweight	$75.00 ➝ $65.00	Low
2/21/2023	Morgan Stanley	Lower Target	Overweight	$80.00 ➝ $73.00	Low
2/16/2023	Stephens	Reiterated Rating	Overweight	$63.00	Low
2/6/2023	The Goldman Sachs Group	Lower Target	Buy	$70.00 ➝ $45.00	Low
1/4/2023	Scotiabank	Initiated Coverage	Sector Outperform	$36.00	Low
12/16/2022	Bank of America	Boost Target		$65.00 ➝ $70.00	Low
12/16/2022	Cowen	Lower Target		$83.00 ➝ $70.00	Low
12/16/2022	BTIG Research	Lower Target		$80.00 ➝ $60.00	Low
12/16/2022	Citigroup	Lower Target		$80.00 ➝ $60.00	Low
11/18/2022	JPMorgan Chase & Co.	Lower Target	Overweight	$100.00 ➝ $85.00	Low
11/7/2022	Stephens	Lower Target	Overweight	$99.00 ➝ $90.00	Low
11/4/2022	The Goldman Sachs Group	Lower Target	Buy	$80.00 ➝ $70.00	Low
11/4/2022	Cowen	Lower Target		$110.00 ➝ $83.00	Low
11/4/2022	Cowen	Lower Target		$110.00 ➝ $83.00	Low
11/4/2022	Credit Suisse Group	Lower Target	Outperform	$80.00 ➝ $70.00	N/A
11/4/2022	Citigroup	Lower Target		$100.00 ➝ $80.00	Low
11/1/2022	Piper Sandler	Downgrade	Overweight ➝ Neutral	$65.00 ➝ $50.00	Low
10/19/2022	Craig Hallum	Initiated Coverage	Buy	$88.00	Low
10/5/2022	Stephens	Initiated Coverage	Overweight	$99.00	Low
8/24/2022	Credit Suisse Group	Initiated Coverage	Outperform	$80.00	Low
8/8/2022	The Goldman Sachs Group	Lower Target	Buy	$90.00 ➝ $80.00	Low
8/8/2022	Morgan Stanley	Lower Target	Overweight	$85.00 ➝ $80.00	Low
8/1/2022	OTR Global	Downgrade	Positive		Low
6/2/2022	Piper Sandler	Initiated Coverage	Overweight	$65.00	High
5/6/2022	Citigroup	Lower Target		$120.00 ➝ $100.00	High
2/24/2022	Stifel Nicolaus	Lower Target	Buy	$160.00 ➝ $130.00	High
2/24/2022	Cowen	Lower Target	Outperform	$170.00 ➝ $110.00	High
2/24/2022	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$180.00 ➝ $165.00	High
2/24/2022	Morgan Stanley	Lower Target	Overweight	$125.00 ➝ $120.00	High
2/24/2022	Wells Fargo & Company	Lower Target	Overweight	$150.00 ➝ $115.00	High
2/24/2022	Citigroup	Lower Target	Buy	$180.00 ➝ $120.00	High
2/24/2022	SVB Leerink	Lower Target	Outperform	$170.00 ➝ $140.00	High
2/15/2022	Morgan Stanley	Lower Target	Overweight	$150.00 ➝ $125.00	Low
11/5/2021	BTIG Research	Reiterated Rating	Buy	$159.00	Low
11/5/2021	SVB Leerink	Lower Target	Outperform	$180.00 ➝ $170.00	High
6/21/2021	Wells Fargo & Company	Boost Target	Overweight	$145.00 ➝ $160.00	Low
6/15/2021	Raymond James	Initiated Coverage	Market Perform		High
6/3/2021	The Goldman Sachs Group	Initiated Coverage	Buy	$160.00	Low
5/27/2021	William Blair	Reiterated Rating	Buy		Low
5/25/2021	Wells Fargo & Company	Initiated Coverage	Overweight	$145.00	Low
5/23/2021	SVB Leerink	Reiterated Rating	Buy		Low
5/7/2021	BTIG Research	Boost Target	Buy	$145.00 ➝ $160.00	Medium
5/7/2021	Morgan Stanley	Lower Target	Overweight	$175.00 ➝ $160.00	High
2/26/2021	Morgan Stanley	Boost Target	Overweight	$130.00 ➝ $175.00	Medium
2/25/2021	Citigroup	Boost Target	Buy	$155.00 ➝ $190.00	High
2/25/2021	Cowen	Boost Target	Outperform	$140.00 ➝ $190.00	High
1/20/2021	SVB Leerink	Boost Target	Outperform	$150.00 ➝ $190.00	Medium
1/11/2021	Stifel Nicolaus	Initiated Coverage	Buy	$175.00	High
12/17/2020	BTIG Research	Boost Target	Buy	$132.00 ➝ $145.00	High
12/16/2020	Smith Barney Citigroup	Boost Target		$145.00 ➝ $155.00	Low
12/11/2020	SVB Leerink	Boost Target	Outperform	$130.00 ➝ $150.00	High
11/12/2020	William Blair	Reiterated Rating	Outperform		Low
11/9/2020	Morgan Stanley	Boost Target	Overweight	$110.00 ➝ $130.00	Medium
11/6/2020	JPMorgan Chase & Co.	Boost Target	Overweight	$120.00 ➝ $135.00	Medium
9/9/2020	Morgan Stanley	Initiated Coverage	Overweight	$110.00	High
6/11/2020	BTIG Research	Initiated Coverage	Buy	$100.00	Low
5/8/2020	SVB Leerink	Reiterated Rating	Buy	$125.00 ➝ $130.00	High
5/8/2020	Citigroup	Boost Target	Buy	$100.00 ➝ $110.00	High
4/23/2020	SVB Leerink	Lower Target	Outperform	$130.00 ➝ $125.00	Medium
2/21/2020	Guggenheim	Initiated Coverage	Buy	$103.00	Medium
1/6/2020	Citigroup	Initiated Coverage	Buy	$100.00	High
11/8/2019	William Blair	Reiterated Rating	Outperform		Low
8/7/2019	Cowen	Set Target	Buy	$110.00	High
8/7/2019	JPMorgan Chase & Co.	Boost Target	Overweight	$90.00 ➝ $135.00	High
5/10/2019	JPMorgan Chase & Co.	Boost Target	Overweight	$85.00 ➝ $90.00	High

(Data available from 4/23/2019 forward)

News Sentiment Rating

0.28 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

9 very positive mentions
5 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

9/26/2023

4 very positive mentions
10 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

10/26/2023

2 very positive mentions
6 positive mentions
0 negative mentions
1 very negative mentions

Mentions as of

11/25/2023

6 very positive mentions
9 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

12/25/2023

7 very positive mentions
2 positive mentions
0 negative mentions
3 very negative mentions

Mentions as of

1/24/2024

4 very positive mentions
14 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/23/2024

13 very positive mentions
14 positive mentions
7 negative mentions
0 very negative mentions

Mentions as of

3/24/2024

10 very positive mentions
9 positive mentions
6 negative mentions
2 very negative mentions

Mentions as of

4/23/2024

Current Sentiment

Recent Stories by Sentiment

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Today's Range

Now: $17.54

$17.35

$17.63

50 Day Range

MA: $19.10

$16.07

$22.83

52 Week Range

Now: $17.54

$15.81

$41.06

Volume

56,010 shs

Average Volume

1,873,500 shs

Market Capitalization

$2.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.87

Frequently Asked Questions

What sell-side analysts currently cover shares of Guardant Health?: The following Wall Street analysts have issued stock ratings on Guardant Health in the last year: Canaccord Genuity Group Inc., Citigroup Inc., Credit Suisse Group AG, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Raymond James, Sanford C. Bernstein, The Goldman Sachs Group, Inc., UBS Group AG, William Blair, and Wolfe Research.
View the latest analyst ratings for GH.
What is the current price target for Guardant Health?: 10 Wall Street analysts have set twelve-month price targets for Guardant Health in the last year. Their average twelve-month price target is $40.40, suggesting a possible upside of 130.3%. Credit Suisse Group AG has the highest price target set, predicting GH will reach $55.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $27.00 for Guardant Health in the next year.
View the latest price targets for GH.
What is the current consensus analyst rating for Guardant Health?: Guardant Health currently has 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for GH.
What other companies compete with Guardant Health?: Other companies that are similar to Guardant Health include Veracyte, Viridian Therapeutics, RadNet, Fortrea and Fulgent Genetics. Learn More about companies similar to Guardant Health.
How do I contact Guardant Health's investor relations team?: Guardant Health's physical mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company's listed phone number is (855) 698-8887 and its investor relations email address is [email protected]. The official website for Guardant Health is www.guardanthealth.com. Learn More about contacing Guardant Health investor relations.

Guardant Health - GH Stock Price Target and Predictions

Analyst Price Target for GH

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.28 (Hold)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Guardant Health?

What is the current price target for Guardant Health?

What is the current consensus analyst rating for Guardant Health?

What other companies compete with Guardant Health?

How do I contact Guardant Health's investor relations team?